RTP Mobile Logo
Challenging Cases in Prostate Cancer: Oncologist and Nurse Investigators Consult on Actual Patients from the Practices of the Invited Faculty
Released July 2013

Video excerpts from the second in a series of 6 integrated symposia held at the 2013 ONS Annual Congress. Featuring perspectives from Drs William K Oh, Ms Doris Pindilli, Dr A Oliver Sartor and Ms Victoria Sinibaldi. (Video Program)

CE Disclosures and Faculty Information

    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of prostate cancer.

    Cancers of the genitourinary system affect hundreds of thousands of individuals within the United States each year, accounting for almost 30% of all newly diagnosed human cancers. Tumors of the prostate are definitively the most prevalent and are thus the topic of extensive ongoing clinical research. Consequently, the clinical management of prostate cancer is frequently in a state of evolution, necessitating rapid and consistent clinician access to emerging data sets of relevance to the continuous delivery of quality cross-functional care.

    These video proceedings from the second part of a 6-part integrated CNE curriculum originally held at the 2013 ONS Annual Congress feature discussions with leading prostate cancer investigators and their nursing counterparts regarding actual patient cases and recent clinical research findings affecting the optimal therapeutic and supportive care for each patient scenario. By providing information on the latest research developments in the context of expert perspectives, this CNE activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with prostate cancer.


    • Discuss the benefits and risks associated with systemic therapies used in the evidence-based treatment of castration-resistant prostate cancer (CRPC), including “secondary” hormonal agents, chemotherapy and immunotherapeutics.
    • Develop a plan to manage the side effects associated with commonly used systemic therapies in CRPC to support patient quality of life and minimize the potential for treatment discontinuation.
    • Review the available efficacy and safety data related to the use of radium-223 chloride and other bone-targeted agents in patients with skeletal metastases to facilitate appropriate counseling for these individuals.
    • Identify opportunities to enhance the collaborative role of oncology nurses in the biopsychosocial care of patients with advanced prostate cancer to optimize clinical and quality-of-life outcomes.
    • Recall ongoing trials of investigational approaches and agents in advanced prostate cancer, and consent and refer patients for study participation.

    Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CNE activity consists of a video component. The participant should watch the video.

    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    William K Oh, MD
    Chief, Division of Hematology and Medical Oncology
    Professor of Medicine and Urology
    Ezra M Greenspan, MD Professor in Clinical Cancer Therapeutics
    Mount Sinai School of Medicine
    Associate Director of Clinical Research
    The Tisch Cancer Institute
    New York, New York

    Consulting Agreements: Amgen Inc, Astellas, Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Dendreon Corporation, Janssen Pharmaceuticals Inc, Medivation Inc, Pfizer Inc, Sanofi; Paid Research: Millennium: The Takeda Oncology Company.

    Doris Pindilli, MS, APN-C, AOCNP
    Advanced Practice Nurse
    Department of Medicine
    The Cancer Institute of New Jersey
    New Brunswick, New Jersey
    Adjunct Faculty Member
    UMDNJ School of Nursing
    Newark, New Jersey

    No real or apparent conflicts of interest to report.

    A Oliver Sartor, MD
    Medical Director, Tulane Cancer Center
    Laborde Professor of Cancer Research
    Professor of Medicine and Urology
    Tulane Medical School
    New Orleans, Louisiana

    Advisory Committee: Bayer HealthCare Pharmaceuticals, Sanofi; Consulting Agreements: Algeta US, Bayer HealthCare Pharmaceuticals, Celgene Corporation, GlaxoSmithKline, Medivation Inc, Millennium: The Takeda Oncology Company, OncoGenex Pharmaceuticals Inc, Pfizer Inc, Sanofi; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Millennium: The Takeda Oncology Company, Sanofi.

    Victoria Sinibaldi, MS, CRNP
    Adult and Geriatric Nurse Practitioner
    Research Associate in Oncology
    Faculty School of Medicine Research
    Program Coordinator, GU Oncology
    Johns Hopkins University
    Baltimore, Maryland

    No real or apparent conflicts of interest to report.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Algeta US/Bayer HealthCare Pharmaceuticals, Astellas/Medivation Inc and Dendreon Corporation.

    Hardware/Software Requirements:
    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch video
(WiFi is recommended for best performance):